Tuesday - July 1, 2025
Results for Johnson & Johnson's Bleximenib Demonstrate Promising Antileukemic Activity in Combination With Venetoclax and Azacitidine for Acute Myeloid Leukemia
June 13, 2025
RARITAN, New Jersey, June 13 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for th . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products